QTTB Stock — Q32 Bio Inc.: Cash, EV, Pipeline

What they do

We are a clinical stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with alopecia areata (“AA”) and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.

Source: 10-K FY2025 via SEC EDGAR

Share price

$9.25

Market cap

$276.8M

Cash

$289.6M

Enterprise value

-$12.8M

Balance sheet

Cash	$289.6M
Debt	$0.0M
Net cash	$289.6M
Enterprise value	-$12.8M
Basic shares	29.9M shares
Fully diluted shares	34.2M shares
Fully diluted market cap	$316.2M
Cash per share	$9.68
Quarterly burn	$3.1M
Cash runway	34.6 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

29.8M

Pre-funded warrants

1.2M

Options

2.3M

RSUs

0.6M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.4M

FDSO

34.2M

Cap table as of 2026-06-30.

Price history

Loading QTTB daily closes…

Loading price history…

Recently reported

bempikibart Mixed · 2026-10-01

bempikibart Phase 2 Positive · 2026-07-13

SIGNAL-AA · alopecia areata

Source release →

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

bempikibart

Phase 2 · Active Modality: monoclonal antibody (fully human)

Aliases ADX-914

Target IL-7Rα

Indications

alopecia areata (AA) (Phase 2)
atopic dermatitis (AD) (Phase 2)

Catalysts

— July 2026
— not dated

Status note Fully human anti-IL-7Rα antibody that re-regulates adaptive immune function. Completed SIGNAL-AA Part A and SIGNAL-AD Phase 2a trials (toplines Dec 2024); company chose to advance AA. SIGNAL-AA Part B dosed first patient April 2025; 36-week topline results announced July 2026. Planned registration-directed program in AA.

ADX-097

Phase 2 · Active Modality: monoclonal antibody fusion protein (anti-C3d)

Target C3d

Status note Phase 2 asset from proprietary tissue-targeted complement inhibitor platform; humanized anti-C3d mAb fusion protein that completed Phase 1 clinical trials. Indication for Phase 2 not stated in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05509023	Phase 2	Active, not recruiting	Sponsor	Q32 Bio Inc.	—	Atopic Dermatitis	—
NCT06018428	Phase 2	Active, not recruiting	Sponsor	Q32 Bio Inc.	—	Alopecia Areata	September 30 - October 3, 2026

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Q32 Bio Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	4,127,987	+1,875,000	1.00%	2026-08-14
Boxer Capital	3,149,310	+3,149,310	3.02%	2026-08-14
BVF Partners	2,350,000	+2,350,000	0.77%	2026-08-14
RA Capital Management	2,332,457	+2,332,457	0.26%	2026-08-14
Logos Global Management	800,000	+800,000	0.44%	2026-08-14
Ikarian Capital	430,000	+430,000	0.90%	2026-08-14
DAFNA Capital	32,896	+32,896	0.08%	2026-08-14
ADAR1 Capital Management	0	-35,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

QTTB — Q32 Bio Inc. ☆

What they do

Balance sheet

Share structure

Price history

Recently reported

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

QTTB — Q32 Bio Inc.